Open Orphan’s Cathal Friel caught up with DirectorsTalk for an exclusive interview to discuss that hVIVO has begun testing of an antiviral for COVID-19 in this exclusive interview with DirectorsTalk.
Open Orphan plc (LON:ORPH) CEO Cathal Friel joins DirectorsTalk to discuss the testing of an anti-viral for treating COVID-19. Cathal explains whats involved in the testing, the time frames involved and
Allergic rhinitis or, as it is commonly known, hay fever, is a reaction to allergens in the air. Most commonly this is a reaction to the pollen count, but can
Open Orphan plc (LON:ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine
Respiratory Syncytial Virus Explained Everybody knows what the common cold and influenza are, but we’d guess not many have heard of RSV (Respiratory Syncytial Virus). So, what it is? Well
Our over-reliance on antibiotics to find relief from numerous ailments, including cold and flu symptoms, is a major health concern – according to the Centers for Disease Control and Prevention.
SARS-CoV-2/COVID-19 has already caused over 50,000 deaths, infected a million people worldwide, triggered massive economic disruption and changed how the entire world moves and interacts. The race to find a
With Marie’s help and encouragement from the scientific group and Cathal Friel, I am re starting “My View” Series which will be as before, a mixture of Science and with
In the UK, one of the centres leading the fight is FluCamp, a 24-bed privately run unit based in Whitechapel, East London, where for the past 30 years scientists have
The first clinical trials are already beginning, but widespread vaccination is still far away. About 20 vaccines for the new type of COVID-19 coronavirus are being developed worldwide. Several countries
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
